Pharmaceutical Sciences Graduate Course, University of Sorocaba, Sorocaba, São Paulo, Brazil.
Dental School, University of Sorocaba, Sorocaba, São Paulo, Brazil.
PLoS One. 2023 Feb 9;18(2):e0281376. doi: 10.1371/journal.pone.0281376. eCollection 2023.
This review of systematic reviews of randomized clinical trials summarized the available evidence regarding the effectiveness and safety of interventions to treat depression and/or anxiety in people with type 1 and type 2 diabetes. The sources of information searched were the Cochrane Library, MEDLINE, EMBASE, Web of Science and LILACS, until up to December 1st, 2022. The interventions were compared with placebo, active control or usual care. The measured primary outcomes were improvement in depression and anxiety remission, reduction of diabetes-specific emotional distress; and improvement in quality of life. Two reviewers, independently, selected the reviews, extracted their data, and assessed their methodological quality using AMSTAR-2. A narrative synthesis of the findings was performed, according to the type of intervention and type of diabetes. Thirteen systematic reviews that included 28,307 participants were analyzed. The reviews had at least one critical methodological flaw. Cognitive Behavioral Therapy improved the mainly depression, glycemic values (n = 5 reviews) and anxiety (n = 1), in adults and elderly with diabetes. Collaborative care (n = 2) and health education (n = 1) improved depression and glycemic values, in adults with diabetes. Pharmacological treatment (n = 2) improved depression outcomes only. The quality of the evidence was low to moderate, when reported. The interventions reported in literature and mainly the Cognitive Behavioral Therapy can be effective to treat people with diabetes and depression; however, some findings must be confirmed. This study can guide patients, their caregivers and health professionals in making decisions concerning the use of these interventions in the mental healthcare of people with diabetes. Protocol Registration: PROSPERO (CRD42021224587).
这篇系统综述的目的是总结干预措施治疗 1 型和 2 型糖尿病患者抑郁和/或焦虑的有效性和安全性的现有证据。检索的信息来源包括 Cochrane 图书馆、MEDLINE、EMBASE、Web of Science 和 LILACS,截至 2022 年 12 月 1 日。干预措施与安慰剂、活性对照或常规护理进行比较。主要结局指标为抑郁和焦虑缓解、糖尿病相关情绪困扰减轻以及生活质量改善。两名审查员独立选择综述、提取数据,并使用 AMSTAR-2 评估其方法学质量。根据干预类型和糖尿病类型,对研究结果进行了叙述性综合。分析了 13 篇综述,共纳入 28307 名参与者。这些综述至少存在一个关键的方法学缺陷。认知行为疗法改善了成年人和老年人糖尿病患者的主要抑郁、血糖值(5 篇综述)和焦虑(1 篇综述)。协作式护理(2 篇综述)和健康教育(1 篇综述)改善了成年糖尿病患者的抑郁和血糖值。药物治疗(2 篇综述)仅改善了抑郁结局。当有报道时,证据质量为低到中。文献中报道的干预措施,主要是认知行为疗法,可以有效治疗患有糖尿病和抑郁症的患者;然而,一些发现需要进一步证实。本研究可以为患者、他们的照顾者和卫生专业人员在决定使用这些干预措施治疗糖尿病患者的心理健康问题时提供指导。方案注册:PROSPERO(CRD42021224587)。